Summit Therapeutics (SMMT) Change in Account Payables (2017 - 2026)

Summit Therapeutics (SMMT) has 10 years of Change in Account Payables data on file, last reported at -$3.9 million in Q2 2026.

• Quarterly Change in Account Payables fell 121.79% year-over-year to -$3.9 million in Q2 2026, while the trailing twelve-month figure through Jun 2026 was -$89000.0 (down 100.45% YoY) and the FY2025 annual result came in at $15.3 million, up 659.45% from the prior year.
• Change in Account Payables fell to -$3.9 million in Q2 2026, from $6.8 million in the prior quarter.
• In the past five years, Change in Account Payables ranged from a high of $17.9 million in Q2 2025 to a low of -$3.9 million in Q2 2026.
• A 5-year average of $1.0 million and a median of $58000.0 in 2023 frame the typical range for Change in Account Payables.
• Annual changes were most pronounced in 2024 — Change in Account Payables slumped 1122.56% — and 2026, when it surged 1810.67%.
• Tracing SMMT's Change in Account Payables over 5 years: stood at -$2.4 million in 2022, then soared by 71.63% to -$672000.0 in 2023, then jumped by 327.53% to $1.5 million in 2024, then slumped by 240.29% to -$2.1 million in 2025, then sank by 82.14% to -$3.9 million in 2026.
• The last three Change in Account Payables figures came in at -$3.9 million (Q2 2026), $6.8 million (Q1 2026), and -$2.1 million (Q4 2025), per Business Quant data.